A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein

被引：17

作者：

Roy, Sylvie ^{[1
]}

Ghani, Karim ^{[1
,2
]}

de Campos-Lima, Pedro O. ^{[3
,4
]}

Caruso, Manuel ^{[1
,2
,5
]}

机构：

[1] Univ Laval, CHU Quebec, Res Ctr, Canc Res Ctr,Oncol Div, Quebec City, PQ, Canada

[2] BioVec Pharma, Quebec City, PQ, Canada

[3] Boldrini Childrens Ctr, Campinas, Brazil

[4] Univ Estadual Campinas, Funct & Mol Biol Grad Program, Campinas, Brazil

[5] Univ Laval, Fac Med, Dept Mol Biol Med Biochem & Pathol, Quebec City, PQ, Canada

来源：

VIRUS RESEARCH | 2021年 / 295卷

关键词：

COVID-19; Coronavirus; SARS-CoV-2; VLP; Virus-like particle; Retrovirus; Moloney; Vaccine; RETROVIRAL VECTORS; FUNCTIONAL RECEPTOR; S-PROTEIN; VACCINES; ENTRY; GLYCOPROTEIN; SUSPENSION; POTENT; CELLS;

D O I：

10.1016/j.virusres.2021.198305

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In this study, we showed that a codon optimized version of the spike (S) protein of SARS-CoV-2 can migrate to the cell membrane. However, efficient production of Moloney murine leukemia (MLV) infectious viral particles was only achieved with stable expression of a shorter S version in C-terminal (Delta S) in MLV Gag-pol expressing cells. As compared to transient transfections, this platform generated viruses with a 1000-fold higher titer. Delta S was 15-times more efficiently incorporated into VLPs as compared to S, and that was not due to steric inter-ference between the cytoplasmic tail and the MLV capsid, as similar differences were also observed with extracellular vesicles. The amount of Delta S incorporated into VLPs released from producer cells was high and estimated at 1.25 mu g/mL S2 equivalent (S is comprised of S1 and S2). The resulting VLPs could potentially be used alone or as a boost of other immunization strategies for COVID-19.

引用

页数：10

共 73 条

[1] SARS-CoV-2 Vaccines: Status Report [J].

Amanat, Fatima ;

Krammer, Florian .

IMMUNITY, 2020, 52 (04) :583-589

[2] Discrimination between exosomes and HIV-1:: Purification of both vesicles from cell-free supernatants [J].

Cantin, Rejean ;

Diou, Juliette ;

Belanger, Dave ;

Tremblay, Alexandre M. ;

Gilbert, Caroline .

JOURNAL OF IMMUNOLOGICAL METHODS, 2008, 338 (1-2) :21-30

[3] Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome Coronavirus by Characterization of a Conspecific Virus from an African Bat [J].

Corman, Victor Max ;

Ithete, Ndapewa Laudika ;

Richards, Leigh Rosanne ;

Schoeman, M. Corrie ;

Preiser, Wolfgang ;

Drosten, Christian ;

Drexler, Jan Felix .

JOURNAL OF VIROLOGY, 2014, 88 (19) :11297-11303

[4] Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays [J].

Crawford, Katharine H. D. ;

Eguia, Rachel ;

Dingens, Adam S. ;

Loes, Andrea N. ;

Malone, Keara D. ;

Wolf, Caitlin R. ;

Chu, Helen Y. ;

Tortorici, M. Alejandra ;

Veesler, David ;

Murphy, Michael ;

Pettie, Deleah ;

King, Neil P. ;

Balazs, Alejandro B. ;

Bloom, Jesse D. .

VIRUSES-BASEL, 2020, 12 (05)

[5] Origin and evolution of pathogenic coronaviruses [J].

Cui, Jie ;

Li, Fang ;

Shi, Zheng-Li .

NATURE REVIEWS MICROBIOLOGY, 2019, 17 (03) :181-192

[6] Highly purified human immunodeficiency virus type 1 reveals a virtual absence of vif in virions [J].

Dettenhofer, M ;

Yu, XF .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1460-1467

[7] A new threat from an old enemy: Re-emergence of coronavirus (Review) [J].

Docea, Anca Oana ;

Tsatsakis, Aristidis ;

Albulescu, Dana ;

Cristea, Oana ;

Zlatian, Ovidiu ;

Vinceti, Marco ;

Moschos, Sterghios A. ;

Tsoukalas, Dimitris ;

Goumenou, Marina ;

Drakoulis, Nikolaos ;

Dumanov, Josef M. ;

Tutelyan, Victor A. ;

Onischenko, Gennadii G. ;

Aschner, Michael ;

Spandidos, Demetrios A. ;

Calina, Daniela .

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 45 (06) :1631-1643

[8] A systematic review of SARS-CoV-2 vaccine candidates [J].

Dong, Yetian ;

Dai, Tong ;

Wei, Yujun ;

Zhang, Long ;

Zheng, Min ;

Zhou, Fangfang .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)

[9] An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates [J].

Erasmus, Jesse H. ;

Khandhar, Amit P. ;

O'Connor, Megan A. ;

Walls, Alexandra C. ;

Hemann, Emily A. ;

Murapa, Patience ;

Archer, Jacob ;

Leventhal, Shanna ;

Fuller, James T. ;

Lewis, Thomas B. ;

Draves, Kevin E. ;

Randall, Samantha ;

Guerriero, Kathryn A. ;

Duthie, Malcolm S. ;

Carter, Darrick ;

Reed, Steven G. ;

Hawman, David W. ;

Feldmann, Heinz ;

Gale, Michael, Jr. ;

Veesler, David ;

Berglund, Peter ;

Fuller, Deborah Heydenburg .

SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (555)

[10] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J].

Folegatti, Pedro M. ;

Ewer, Katie J. ;

Aley, Parvinder K. ;

Angus, Brian ;

Becker, Stephan ;

Belij-Rammerstorfer, Sandra ;

Bellamy, Duncan ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Clutterbuck, Elizabeth A. ;

Dold, Christina ;

Faust, Saul N. ;

Finn, Adam ;

Flaxman, Amy L. ;

Hallis, Bassam ;

Heath, Paul ;

Jenkin, Daniel ;

Lazarus, Rajeka ;

Makinson, Rebecca ;

Minassian, Angela M. ;

Pollock, Katrina M. ;

Ramasamy, Maheshi ;

Robinson, Hannah ;

Snape, Matthew ;

Tarrant, Richard ;

Voysey, Merryn ;

Green, Catherine ;

Douglas, Alexander D. ;

Hill, Adrian V. S. ;

Lambe, Teresa ;

Gilbert, Sarah C. ;

Pollard, Andrew J. .

LANCET, 2020, 396 (10249) :467-478

← 1 2 3 4 5 6 7 8 →